These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant. Douxfils J; Beaudart C; Dogné JM Lancet; 2023 Nov; 402(10413):1623-1625. PubMed ID: 37865107 [No Abstract] [Full Text] [Related]
5. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2). Santoro N; Nappi RE; Neal-Perry G; English M; King DD; Yamaguchi Y; Ottery FD Menopause; 2024 Apr; 31(4):247-257. PubMed ID: 38517210 [TBL] [Abstract][Full Text] [Related]
7. More promising news (mostly) on manipulating neurokinin B activity as a nonhormonal treatment of hot flashes. Reame NK Menopause; 2020 Apr; 27(4):375-376. PubMed ID: 32132443 [No Abstract] [Full Text] [Related]
8. Fezolinetant: First Approval. Lee A Drugs; 2023 Aug; 83(12):1137-1141. PubMed ID: 37462862 [TBL] [Abstract][Full Text] [Related]
9. Scaffold hopping of fused piperidine-type NK3 receptor antagonists to reduce environmental impact. Yamamoto K; Inuki S; Ohno H; Oishi S Bioorg Med Chem; 2019 May; 27(10):2019-2026. PubMed ID: 30975505 [TBL] [Abstract][Full Text] [Related]
10. Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal. Gompel A; Stuenkel CA Cell Rep Med; 2023 Jun; 4(6):101076. PubMed ID: 37343519 [TBL] [Abstract][Full Text] [Related]
11. Deal watch: Neurokinin 3 receptor antagonist revival heats up with Astellas acquisition. Cully M Nat Rev Drug Discov; 2017 May; 16(6):377. PubMed ID: 28559557 [No Abstract] [Full Text] [Related]
12. Fezolinetant. Am J Health Syst Pharm; 2023 Aug; 80(17):1113-1114. PubMed ID: 37382493 [No Abstract] [Full Text] [Related]
14. Fezolinetant (Veozah) for the Treatment of Menopause Symptoms. Crespo C; Erlich D Am Fam Physician; 2024 Mar; 109(3):273-274. PubMed ID: 38574221 [No Abstract] [Full Text] [Related]
15. Finding SKYLIGHT for all: fezolinetant efficacy for vasomotor symptoms in subpopulations. Reed SD Menopause; 2024 Apr; 31(4):245-246. PubMed ID: 38517209 [No Abstract] [Full Text] [Related]
16. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council. Wright AC; Beaudoin FL; McQueen RB; Yeung K; Moradi A; Herron-Smith S; Gutierrez E; Lin GA; Pearson SD J Manag Care Spec Pharm; 2023 Jun; 29(6):692-698. PubMed ID: 37276043 [No Abstract] [Full Text] [Related]